Using platelet-rich plasma to treat knee osteoarthritis
Efectividad Del Plasma Rico en Plaquetas (PRP) Para la disminución Objetiva Del Dolor y la recuperación Funcional Del Miembro Inferior en Osteoartritis de Rodilla. Evaluación de Alternativas metodológicas
PHASE2 · Universidad Nacional de Entre Rios · NCT05825105
This study is testing two different ways of using platelet-rich plasma to see which one helps people with knee osteoarthritis feel less pain and move better.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 110 (estimated) |
| Ages | 35 Years and up |
| Sex | All |
| Sponsor | Universidad Nacional de Entre Rios (other) |
| Locations | 1 site (Oro Verde, Entre Ríos) |
| Trial ID | NCT05825105 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of platelet-rich plasma (PRP) treatment for patients suffering from knee osteoarthritis (OA). It aims to compare two different methods of PRP application to determine which is more effective in reducing pain and improving joint function. Participants will be assessed using the WOMAC scale and other measures to gauge their response to the treatment. The study seeks to optimize PRP preparation and identify patient characteristics that may influence treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates are individuals over 35 years old with a radiological diagnosis of knee osteoarthritis and a WOMAC score of 24 or higher.
Not a fit: Patients with knee prostheses, rheumatoid arthritis, or other specified blood disorders will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce pain and improve mobility for patients with knee osteoarthritis.
How similar studies have performed: Previous studies have shown promising results with platelet-rich plasma treatments for osteoarthritis, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Radiological diagnosis of knee OA * Age over 35 years old * WOMAC value of 24 or higher at the time of recruitment Exclusion Criteria: * Patients with knee prosthesis, rheumatoid arthritis, contralateral lower limb amputation, any type of blood dyscrasia, hypofibrinogenemia, depot pool syndrome, or any other form of thrombocytopathy or chronic leukocytosis will be excluded from the study. * Patients with anticoagulant or acute coagulopathies, as well as carriers of any infectious disease or superficial infection at the puncture site, will be temporarily excluded from the study until their clinical recovery is confirmed by laboratory testing.
Where this trial is running
Oro Verde, Entre Ríos
- Institute for Research and Development in Bioengineering and Bioinformatics (IBB-CONICET-UNER) — Oro Verde, Entre Ríos, Argentina (RECRUITING)
Study contacts
- Study coordinator: Pablo Schierloh, PhD
- Email: pablo.schierloh@uner.edu.ar
- Phone: +5491131325656
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Knee Osteoarthritis, Autologous Treatments, Public Health, Lower Extremity, Argentina, Real-world studies